{"doi":"10.17615/ybp3-b890","title":"Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice","abstract":"Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.","journal":"UNC Libraries","year":2021,"id":229838,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9618,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":105503,"name":"Boyd L. Yount","orcid":"0000-0002-6099-8429","position":1,"is_corresponding":false},{"id":105115,"name":"Stephanie A. Montgomery","orcid":"0000-0001-8012-5302","position":2,"is_corresponding":false},{"id":540773,"name":"David R. Martinez","orcid":"0000-0002-1689-5529","position":3,"is_corresponding":false},{"id":105124,"name":"Tomáš Cihlář","orcid":"0000-0001-6840-0885","position":4,"is_corresponding":false},{"id":620319,"name":"Dapeng Li","orcid":"0000-0002-6105-8885","position":5,"is_corresponding":false},{"id":96347,"name":"Barton F. Haynes","orcid":"0000-0002-7643-9023","position":6,"is_corresponding":false},{"id":104187,"name":"Michel C. Nussenzweig","orcid":"0000-0003-0592-8564","position":7,"is_corresponding":false},{"id":5953,"name":"Timothy P. Sheahan","orcid":"0000-0001-9181-2183","position":8,"is_corresponding":false},{"id":5952,"name":"Ralph S. Baric","orcid":"0000-0001-6827-8701","position":9,"is_corresponding":false},{"id":105122,"name":"Danielle Porter","orcid":"0000-0001-8459-2370","position":10,"is_corresponding":false},{"id":639915,"name":"Elaine Bunyan","orcid":"0000-0002-8743-1879","position":11,"is_corresponding":false},{"id":105123,"name":"Joy Y. Feng","orcid":"0000-0003-4837-1911","position":12,"is_corresponding":false},{"id":105603,"name":"Kendra L. Gully","orcid":"0000-0001-5742-2341","position":13,"is_corresponding":false},{"id":105111,"name":"Sarah R. Leist","orcid":"0000-0002-4989-5381","position":14,"is_corresponding":false},{"id":590473,"name":"Alexandra Schäfer","orcid":"0000-0002-4760-4923","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T23:55:01.675482Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}